Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 374 results for "Victoza"

Novo Nordisk Quarterly Profit Misses Estimates on Victoza

Novo Nordisk Quarterly Profit Misses Estimates on Victoza

Novo Nordisk A/S, the world's largest maker of insulin, reported fourth-quarter earnings that missed analysts estimates as sales of its key diabetes drug Victoza rose less than expected. Profit rose to 8.26 billion kroner ($1.21 billion), the ... Bloomberg, 1 week ago

1 images for "Victoza"

Bloomberg, 1 week ago

Victoza(R) (liraglutide) provides greater glycaemic control than SGLT-2 inhibitors

VANCOUVER, Canada , Dec. 2, 2015 /PRNewswire/ — New findings from a network meta-analysis show that treatment with Victoza® (liraglutide) provides a greater HbA1c reduction and an improved likelihood of reaching glycaemic goals compared to ...
 PharmaVOICE2 months ago BRIEF-Novo Nordisk presents new Victoza, Ryzodeg results  Reuters UK2 months ago Novo Nordisk says Victoza provides greater HbA1c reductions than SGLT2 inhibitors  FirstWord Pharma2 months ago Victoza® (liraglutide) provides greater glycaemic control than SGLT-2 inhibitors  Ulitzer2 months ago

Victoza reduces BMI, other variables in NASH

Researchers found that Victoza successfully reduced BMI, cholesterol-low density lipoprotein and other clinical variables in patients with nonalcoholic steatohepatitis, according to data published in the Journal of Hepatology . Liraglutide ...
 Orthopedics Today1 day ago

Novo Nordisk strikes back with SGLT2-beating data on Victoza

Novo Nordisk is striking back against the SGLT2 drug class. Maker of the blockbuster GLP-1 diabetes drug Victoza, Novo rolled out a new meta-analysis showing that its med beat those in the other class at reducing the blood sugar metric HbA1c.
 FiercePharmaMarketing2 months ago Novo touts SGLT2-topping data for blockbuster Victoza  FiercePharma2 months ago Novo Nordisk buys Xoma diabetes program and scores trial successes  Pharmafile2 months ago Novo Nordisk Takes NASH Treatment Another Step Forward  Seeking Alpha1 week ago

Novo Nordisk's Q4 profit up 26 percent, but falls short of estimates on Victoza

Novo Nordisk announced Wednesday that fourth-quarter profit reached 8.3 billion kroner ($1.2 billion), up 26 percent year-over-year, although the figure fell short of analyst estimates of 8.5 billion kroner ($1.2 billion). Sales in the three-month ...
 FirstWord Pharma1 week ago

Medical News Today: Type 2 diabetes: long-term liraglutide use may raise blood sugar levels

Liraglutide is a drug used to lower blood sugar levels for people with type 2 diabetes. However, a new study suggests that long-term use of the medication may do just the opposite. Long-term liraglutide use may increase blood sugar levels rather ...
 Medical News Today4 hours ago Medical Information In the present day: Sort 2 diabetes: lengthy-time period liraglutide use might increase blood sugar ranges  9ija News.com5 hours ago Popular Diabetes Drug Found To Lose Its Effectiveness Over Time  Medical Daily14 hours ago

Matrin Shkreli Is Insufferable (and I Would Be, Too)

When Pharmabro Martin Shkreli appeared before a House Committee meeting last week and took the fifth, he was soundly mocked. And so would I have been, had I appeared instead. You can believe that if I am ever subpoenaed for any reason, I will answer ...
 Daily Kos13 hours ago
Pharma Letter

Competition from Lilly's Trulicity weighs on Novo's otherwise solid Q4

Dive Brief: Novo Nordisk had a slightly weaker quarter than expected, due in large part to the competitive impact of Eli Lilly's Trulicity entering the market.Overall Q4 2015 profit was up 26% to 8.26 billion kroner—but less than analysts had ...
 BioPharma Dive1 day ago Sanofi (SNY) Olivier Brandicourt on Q4 2015 Results - Earnings Call Transcript  Seeking Alpha2 days ago How Novo's Diabetes and Obesity Care Segment Performed in 4Q15  Yahoo! Finance3 days ago Why Novo Nordisk Fell after Its 4Q15 Earnings Release  Yahoo! Finance3 days ago

NPS+ Type 2 Diabetes Mellitus (EU5)

LONDON, Feb. 10, 2016 /PRNewswire/ -- How loyal are doctors to your Type 2 Diabetes Mellitus (T2DM) brand? How many other brands do they recommend? Which ones? What can you do to set your brand apart and win more market share? Get the answers in ...
 TickerTech.com1 day ago
Digital Journal

Asia-Pacific Type 2 Diabetes Mellitus Therapeutics Markets to 2021 Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth

Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia high blood glucose levels that results from defects in insulin secretion, insulin action, or a combination of these. This chronic hyperglycemia is associated ...
 Before It's News4 days ago Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth  Tutorial Finder1 day ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Victoza
Get updated on latest news & your favorite topics right in your inbox!
More     Less